-1753895929355.webp&w=3840&q=75)
2025 NOSCM | Chimeric Antigen Receptor T-cell Therapy in B-cell lymphomas: Is Cure A Reality or Is It Still Just A Promise?
Overview
Dr. Mohamed Kharfan-Dabaja covered CAR T-cell therapy for B-cell lymphomas, showing 5-year survival of 42.6% in mantle cell cases and 64% in early remissions. Early use improved PFS. Prognostic factors included male sex, LDH, and bilirubin. Despite risks like secondary cancers, benefits extend even to octogenarians.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Mohamed A. Kharfan-Dabaja, MD, MBA, FACP
Date of Release
July 30th, 2025
-1755991489210.webp&w=3840&q=75)
-1755991393648.webp&w=3840&q=75)